Drug concentration monitoring

Drug concentration monitoring

The domestic drug concentration monitoring market is at an initial stage. According to the Investment Feasibility Study Report of China Therapeutic Drug Monitoring (TDM) Project, 2021 to 2025, the percentage of medical institutions above Class III that carry out therapeutic drug monitoring is about 40%, with blood drug concentration monitoring accounting for 60% of the total. The AGNP Consensus Guideline for Therapeutic Drugs Monitoring in Psychiatry: 2011 has specified 128 psychotropic drugs that require drug concentration monitoring, and the Expert Consensus for Monitoring Therapeutic Drugs in Children states that 15 drugs require drug concentration monitoring. Previously, drugs subject to drug concentration monitoring were mainly psychotropic drugs and immunosuppressants, which were mandated by the state. In future, with the popularity of the concept of individualized treatment, more drugs will be included in the scope of drug concentration monitoring under the backdrop of precision medicine.

It is difficult to accurately detect drugs with low concentration in the blood, such as novel drugs, tumor-targeted drugs, toxic drugs, antibiotic drugs, and cardiovascular drugs, using traditional methodologies. Mass spectrometric analysis can reach the sensitivity of pg/mL level, and many different types of drugs can be detected. The application of mass spectrometry technology in drug concentration monitoring is set to grow rapidly.

The monitored drugs include: antibiotics, immunosuppressive agents, theophylline, anti-tuberculosis, anti-tumor, psychotropic drugs, anti-epilepsy, cardiovascular drugs, targeted drugs, amino acids, and pesticide poisons.